Management of corticosteroid‐induced osteoporosis

Journal of Internal Medicine

Volumn 237, Issue 5, 1995, Pages 439-447

  EASTELL, RICHARD ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CONJUGATED ESTROGEN; CORTICOSTEROID; DEFLAZACORT; ETIDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PREDNISOLONE; PREDNISONE; VITAMIN D DERIVATIVE;

BONE DEVELOPMENT; DENSITOMETRY; FEVER; FRACTURE; GASTROINTESTINAL DISEASE; HORMONE SUBSTITUTION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LEUKOPENIA; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

EID: 0029054385     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.1995.tb00868.x     Document Type: Review

References (64)

1. Steroid‐induced fractures and bone loss in patients with asthma
2. Fractures after rheumatoid arthritis. A population‐based study
3. Rheumatoid arthritis, corticosteroid therapy and the risk of hip fracture
4. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man
5. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids
6. Risk of vertebral fracture in women with rheumatoid arthritis
7. Bone density at various sites for prediction of hip fractures
8. Vertebral fractures in steroid dependent asthma and involutional osteoporosis: a comparative study
9. Prevention of corticosteroid osteoporosis ‐ a comparison of calcium, calcitriol, and calcitonin
10. Corticosteroid effects on proximal femur bone loss
11. Lateral spine densitometry is a more sensitive indicator of glucocorticoid‐induced bone loss
12. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis ‐ effects of low‐dose corticosteroids
13. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content
14. Bone density in asthmatic patients taking high dose inhaled beclomethasone diproprionate and intermittent systemic corticosteroids
15. Contrasting microanatomy of idiopathic and corticosteroid‐induced osteoporosis
16. Bone loss in response to long‐ term glucocorticoid therapy
17. Histomorphometric profile, pathophysiology and reversibility of corticosteroid‐induced osteoporosis
18. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long‐term glucocorticoid treatment
19. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid‐induced osteoporosis
20. Cancellous bone remodelling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels
21. Serum osteocalcin (bone Gla‐protein) and steroid osteoporosis in rheumatoid arthritis
22. Effect of short‐term glucocorticoids on serum osteocalcin in healthy young men
23. The effects of high‐dose glucocorticoid administration on serum bone gamma carboxyglutamin acid ‐ containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects
24. The course of biochemical parameters of bone turnover during treatment with corticosteroids
25. Low serum osteocalcin levels in glucocorticoid‐treated asthmatics
26. Relationship of glucocorticoid dosage to serum bone gla‐protein concentration in patients with rheumatologic disorders
27. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin
28. 3, parathyroid hormone, and glucocorticoids
29. Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen
30. Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis
31. Glucocorticoid‐induced osteoporosis: pathogenesis and management
32. Glucocorticoids decrease vitamin D receptor numbers and gene expression in human osteosarcoma cells
33. Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism in man
34. Acute changes in urinary radiocalcium following glucocorticoid administration in man
35. The crush fracture syndrome in postmenopausal women
36. Bone turnover during high dose inhaled corticosteroid treatment
37. Corticosteroids and osteoporosis
38. Steroid osteoporosis
39. Mechanism of development of glucocorticoid‐induced osteoporosis and its treatment. Intestinal calcium absorption and vitamin D metabolism in patients under glucocorticoid therapy and correction of secondary hyper parathyroidism
40. Calcium and phosphorus homeostasis in man. Effect of corticosteroids
41. Effect of glucocorticoids on function of the parathyroid glands in man
42. Osteopenia in patients with rheumatic diseases: principles of diagnosis and therapy
43. The assessment of the systemic effects of inhaled glucocorticosteroids ‐ the effects of inhaled budesonide vs. oral prednisolone on calcium metabolism
44. Elevated 1,25‐dihydroxyvitamin‐D levels in patients with chronic obstructive pulmonary disease treated with prednisone
45. Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment
46. Malabsorption of calcium in corticosteroid‐ induced osteoporosis
47. Calcium absorption in corticoid treated subjects: effects of a single oral dose of calcitriol
48. Evidence for decreased tubular reabsorption of calcium in glucocorticoid‐treatment asthmatics
49. Hormonal status in normal, osteoporotic and corticosteroid‐treated postmenopausal women
50. Glucocorticoid inhibition of FSH‐induced estrogen production in cultured rat granulosa cells
51. Effect of low doses of deflazacort vs. prednisone on bone mineral content in premenopausal rheumatoid arthritis
52. The prevention and treatment of osteoporosis
53. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
54. Intermittent cyclical etidronate in the prevention of steroid‐induced bone loss
55. Prevention of glucocorticoid‐induced osteoporosis
56. Prevention of serioid‐induced osteoporosis with (3‐amino‐hydroxypropylidene)‐1,1, disphosphonate (APD)
57. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study
58. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid‐induced bone loss
59. Estrogen and progesterone replacement therapy reduces glucocorticoid‐induced bone loss
60. Increased serum concentrations of type‐I procollagen C‐terminal propeptide and osteocalcin during a short course of calcitriol administration to adult male volunteers
61. Altered mineral metabolism in glucocorticoid‐lnduced osteopenia: Effect of 25‐hydroxyvitamin D administration
62. Bone metabolism in patients with rheumatoid arthritis
63. Prevention of corticosteroid‐induced osteoporosis with salmon calcitonin in sarcoid patients